Gain Therapeutics Inc (NASDAQ:GANX) has a beta value of 0.13 and has seen 0.53 million shares traded in the recent trading session. The company, currently valued at $47.02M, closed the recent trade at $1.57 per share which meant it lost -$0.13 on the day or -7.65% during that session. The GANX stock price is -103.18% off its 52-week high price of $3.19 and 43.31% above the 52-week low of $0.89. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.3 million shares traded. The 3-month trading volume is 284.87K shares.
The consensus among analysts is that Gain Therapeutics Inc (GANX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 13 have rated it as a Hold, with 12 advising it as a Buy. 0 have rated the stock as Underweight.
Gain Therapeutics Inc (NASDAQ:GANX) trade information
Sporting -7.65% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the GANX stock price touched $1.57 or saw a rise of 18.86%. Year-to-date, Gain Therapeutics Inc shares have moved 13.77%, while the 5-day performance has seen it change -11.30%. Over the past 30 days, the shares of Gain Therapeutics Inc (NASDAQ:GANX) have changed -9.25%. Short interest in the company has seen 0.23 million shares shorted with days to cover at 0.98.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 77.57% from the levels at last check today.. The projected low price target is $4.0 while the price target rests at a high of $10.0. In that case, then, we find that the latest price level in today’s session is -536.94% off the targeted high while a plunge would see the stock gain -154.78% from the levels at last check today..
Gain Therapeutics Inc (GANX) estimates and forecasts
The company’s shares have lost -28.31% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -37.02% over the past 5 years. Earnings growth for 2025 is a modest 29.96% while over the next 5 years, the company’s earnings are expected to increase by 5.12%.
GANX Dividends
Gain Therapeutics Inc is expected to release its next earnings report on 2025-May-14 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Gain Therapeutics Inc (NASDAQ:GANX)’s Major holders
Insiders own 4.42% of the company shares, while shares held by institutions stand at 9.53% with a share float percentage of 9.97%. Investors are also buoyed by the number of investors in a company, with Gain Therapeutics Inc having a total of 38.0 institutions that hold shares in the company. The top two institutional holders are TIMELO INVESTMENT MANAGEMENT INC. with over 0.61 million shares worth more than $0.77 million. As of 2024-06-30, TIMELO INVESTMENT MANAGEMENT INC. held 3.3666% of shares outstanding.
The other major institutional holder is DME CAPITAL MANAGEMENT, LP, with the holding of over 0.57 million shares as of 2024-06-30. The firm’s total holdings are worth over $0.72 million and represent 3.1488% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 0.82% shares in the company for having 245.47 shares of worth $0.39 million while later fund manager owns 145.88 shares of worth $0.23 million as of May 31, 2025 , which makes it owner of about 0.49% of company’s outstanding stock.
